✦ LIBER ✦

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

✍ Scribed by Irene M. Ghobrial; Nikhil C. Munshi; Brianna N. Harris; Peipei Shi; Nichole M. Porter; Robert L. Schlossman; Jacob P. Laubach; Kenneth C. Anderson; Durisala Desaiah; Scott P. Myrand; James E. Wooldridge; Paul G. Richardson; Rafat Abonour

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 209 KB
Volume: 86
Category: Article
ISSN: 0361-8609
DOI: 10.1002/ajh.22048

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An open-label, phase 2 trial of denosuma

An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma

✍ Ravi Vij; Noemi Horvath; Andrew Spencer; Kerry Taylor; Saroj Vadhan-Raj; Robert 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

Hyperthermia for the treatment of patien

Hyperthermia for the treatment of patients with malignant germ cell tumors : A Phase I/II study in ten children and adolescents with recurrent or refractory tumors

✍ Rüdiger Wessalowski; Heidi Kruck; Hildegard Pape; Thomas Kahn; Reinhart Willers; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

waves in combination with platinum-based chemotherapy in ten children and 4 Institute of Statistics, Heinrich-Heine Univeradolescents with recurrent or refractory GCTs. sity, Du ¨sseldorf, Germany. ## RESULTS. Seven of ten patients with recurrent or refractory GCTs had objective responses. Of the

A phase III study of radiation therapy p

A phase III study of radiation therapy plus carmustine with or without recombinant interferon-α in the treatment of patients with newly diagnosed high-grade glioma

✍ Jan C. Buckner; Paula J. Schomberg; William L. McGinnis; Terrence L. Cascino; Be 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 235 KB 👁 2 views

Phase I clinical study of a static magne

Phase I clinical study of a static magnetic field combined with anti-neoplastic chemotherapy in the treatment of human malignancy: Initial safety and toxicity data

✍ Joseph R. Salvatore; Joanne Harrington; Thomas Kummet 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB

Phase I trial of paclitaxel, carboplatin

Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer

✍ John D. Hainsworth; Howard A. Burris III; Lisa H. Morrissey; F. Anthony Greco 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 2 views

## Background: Topotecan is a new antineoplastic agent with a broad spectrum of activity. the purpose of this phase i trial was to define the maximum tolerated dose of topotecan when added to the widely used combination of paclitaxel and carboplatin. ## Methods: Patients with advanced cancer that

The addition of interferon or high dose

The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma : Phase III Eastern Cooperative Oncology Group clinical trial EST 9486

✍ Martin M. Oken; Traci Leong; Raymond E. Lenhard Jr.; Philip R. Greipp; Neil E. K 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 133 KB 👁 2 views

## BACKGROUND. Interferon (IFN) has demonstrated activity in the treatment of patients with multiple myeloma. A previous Eastern Cooperative Oncology Group (ECOG) study suggested that the rates of complete response (CR) and survival were increased with a regimen that alternated IFN with chemothera